539 results on '"Marais R"'
Search Results
2. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers
3. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
4. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
5. Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
6. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
7. Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
8. Consensus on precision medicine for metastatic cancers: a report from the MAP conference
9. A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
10. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition
11. Isolation and Characterization of SRF Accessory Proteins
12. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers
13. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages
14. The role of signaling pathways in the development and treatment of hepatocellular carcinoma
15. 2236P MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
16. La galerie des oiseaux
17. La galerie des oiseaux
18. La galerie des oiseaux
19. La galerie des oiseaux
20. Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis
21. Elucidating distinct roles for NF1 in melanomagenesis
22. COX2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors
23. Melanoma therapy: from frustration to enthusiasm
24. Paradoxical activation of the MEK/ERK pathway promotes melanoma invasion and metastasis: P06-153
25. Symptomatic hepatothorax presenting 25 years after penetrating thoracoabdominal injury
26. In Melanoma RAS Mutations are Accompanied by Switching Signalling from BRAF to CRAF and Disrupted cAMP Signalling
27. BRAF, AN ONCOGENE AND THERAPEUTIC TARGET IN MELANOMA
28. PKA regulates 14-3-3 binding to Raf-1: SL05-033
29. Short communications: The first documented record of Western Reef Heron Egretta (gularis) schistacea for Tanzania
30. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
31. Circulating tumour DNA analysis predicts relapse following resection in stage II and III melanoma
32. Erratum: Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma (Cancer Cell (2015) 27(1) (85–96) (S1535610814004577) (10.1016/j.ccell.2014.11.006))
33. Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression
34. Nodular Melanoma: A Histopathologic Entity?
35. Development of the Manchester Cancer Research Centre Molecular Tumour Board for matching patients to clinical trials based on tumour and ctDNA genetic profiling
36. 141 Targeting TGFβ signaling in BRAF mutant melanoma
37. MAPK pathway activation in the embryonic pituitary results in stem cell compartment expansion, differentiation defects and provides insights into the pathogenesis of papillary craniopharyngioma
38. UM Cure 2020 - A consortium of European experts in uveal melanoma to identify new therapies for patients with metastatic disease
39. Prostate cancer: A personalised approach through the development of patient-derived xenografts
40. Metabolic rewiring in melanoma cell lines that acquired resistance to BRAF inhibitors
41. Gene-specific interactions between ultraviolet radiation and melanoma
42. Tumour–microenvironment mediates resistance to immuno and targeted therapies in acral melanoma
43. Systematic longitudinal analysis of circulating tumour DNA in melanoma patients undergoing systemic therapy
44. Lysyl oxidase regulates EGFR signalling through the extracellular matrix
45. BRAF inhibition promotes BRAF mutant human melanoma cell survival under nutrient-deprived conditions through activation of mitochondrial metabolism
46. Proffered Paper: Utilising non-mutational drug-tolerance prolongs and improves targeted melanoma therapy
47. The role of BAP1 loss of function in uveal melanoma
48. Modelling anti-PD-1 treatment in a transgenic murine model of BRAFV600E-driven melanoma
49. Therapeutic efficacy of the paradox-breaking panRAF and SRC drug CCT3833/BAL3833 in KRAS-driven cancer models
50. Genomic analysis of multi-site fresh prostate samples
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.